Immunotec Oxford Raises $64m in Nasdaq IPO
25th November 2013
Oxford Immunotec – a 2002 Isis spin-out – has raised US$64 million in an IPO on America’s Nasdaq stock exchange. The Abingdon-based company sells diagnostic tests for latent tuberculosis infection, T-SPOT®.TB.
The T-SPOT®.TB tests replace the century-old tuberculin skin test, which can generate a high frequency of false signals and can be problematic to perform. T-SPOT®.TB is already selling widely in many countries.
Dr Peter-Wrighton Smith, Oxford Immunotec’s CEO, has been with the company since its 2002 launch, having been brought in as a manager for the spinout by Isis.
Immunotec Oxford and also has a US presence.
The company’s shares trade on Nasdaq under the symbol “OXFD”.
Press release sign up
© Oxford University Innovation